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disease, any valve prosthesis, acute coronary 
syndrome or ischemic stroke within the pre‑
vious 6 months, or potent drug ‑drug interac‑
tions with anticancer agents (which are listed 
by Steffel et al3).
Anemia was recognized if hemoglobin lev‑
els were lower than 12  g/dl in women and 
lower than  13  g/dl in men. Thrombocyto‑
penia was defined as a platelet count of less 
than 100 × 103/μl.4,5 Renal failure was diagnosed 
when creatinine clearance was below 60 ml/min. 
The study protocol was approved by the Ethics 
Committee of Jagiellonian University (Kraków, 
Poland). All patients gave written informed con‑
sent to participate in the study.
Follow ‑up The follow ‑up started at the initiation 
of anticoagulation with a NOAC. Arterial and ve‑
nous thromboembolic episodes as well as death 
were recorded based on medical records and histo‑
ry taken at clinic visits or by phone calls. Follow‑
ing stroke or thrombosis, patients received hepa‑
rins at therapeutic doses and most of them con‑
tinued parenteral anticoagulation. Major and clin‑
ically relevant nonmajor bleedings as well as with‑
drawal of NOAC treatment were also recorded.6
Statistical analysis Statistical analysis was per‑
formed with the Statistica 12.5 software (Stat‑
Soft, Tulsa, Oklahoma, United States). Con‑
tinuous variables were expressed as medi‑
an (interquartile range) and categorical  vari‑
ables as number (percentage), as appropri‑
ate. Continuous variables were compared with 
Introduction Atrial fibrillation (AF) is the most 
common sustained cardiac arrhythmia observed 
in patients with cancer. A recent meta ‑analysis 
has shown that non–vitamin K antagonist oral 
anticoagulants (NOACs) used in AF patients with 
cancer reduce the risk of stroke or systemic em‑
bolism by 48% and intracranial or gastrointes‑
tinal bleedings by 35% as compared with warfa‑
rin.1 In patients with cancer ‑associated thrombo‑
sis, extended treatment with NOACs is associat‑
ed with similar effectiveness and safety as low‑
‑molecular ‑weight heparins.2 However, there are 
limited data on the use of NOACs in patients with 
AF and specific types of cancer.1,3 Therefore, we 
sought to investigate the effectiveness and safe‑
ty of NOACs in patients with AF and colorectal 
cancer.
Methods In this cohort study, we enrolled 
44 consecutive ambulatory patients with ac‑
tive colorectal cancer and documented AF, who 
were referred to our center for further diagnostic 
workup between January 2013 to January 2017. 
Patients with colorectal cancer with life expec‑
tancy longer than 1 year who received chemo‑
therapy, were diagnosed within the previous 
6 months, or had recurrent or metastatic can‑
cer were eligible. All patients refused to be treat‑
ed with warfarin or heparins on a long ‑term ba‑
sis. We excluded patients with a history of se‑
rious gastrointestinal or intracranial bleeding, 
hemoglobin levels lower than 9 g/dl, thrombo‑
cytopenia (platelet count, <50 × 103/μl), stage 4 
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dose of NOAC (n = 20, 45.5%) more often had re‑
nal failure, prior stroke, and prior major bleed‑
ing compared with the remaining patients (TABLE 1).
Within the median follow ‑up of 28.5 months, 
26 patients died (59.1%, 23.6%/year). The over‑
all NOAC withdrawal rate was 34.1% (16%/year). 
Ischemic stroke or transient ischemic attack oc‑
curred in 5 patients (11.4%, 4.9%/year) with a me‑
dian CHA2DS2‑VASc of 1 at a mean age of 68 years 
(median time since NOAC initiation, 15 months), 
including 1 patient on dabigatran (110 mg twice 
daily), 2 patients on rivaroxaban (15 mg once dai‑
ly), and 2 patients on apixaban (2.5 mg twice daily). 
Two of these patients had prior ischemic stroke or 
transient ischemic attack before NOAC initiation. 
Two patients on apixaban (2.5 mg twice daily) ex‑
perienced deep vein thrombosis (4.5%, 1.9%/year), 
without symptomatic pulmonary embolism on 
the Mann–Whitney test. Categorical variables 
were analyzed by the χ2 test or Fisher exact test. 
The Cox proportional hazard regression was used 
to determine independent predictors of sur‑
vival free of thromboembolic events. A 2‑sided 
P of less than 0.05 was considered significant.
RESULTS The characteristics of the study group 
are shown in TABLE 1. Most patients had perma‑
nent AF. The median time since cancer diagno‑
sis to NOAC initiation was 6 months. The major‑
ity of patients received rivaroxaban. In this sub‑
group, the prevalence of renal failure was lower 
as compared with patients on dabigatran (15% vs 
64%; P = 0.02). Patients on apixaban were older 
compared with the dabigatran group (70 years vs 
59 years; P <0.001). Patients receiving a reduced 
TABLE 1 Baseline characteristics and clinical outcomes of the studied patients (continued on the next page)
Parameter All patients 
(n = 44)
Full dose of NOAC  
(n = 24)
Reduced dose of NOAC 
(n = 20)
Age, y 67 (60.5–70) 67.5 (62–70) 63 (59–73)
Male sex 17 (38.6) 10 (41.7) 7 (35)
Body mass index, kg/m2 27 (24.3–31.3) 27 (24.5–31.4) 26.8 (22.9–31.1)
Active smoking 18 (40.9) 8 (33.3) 10 (50)
Hypertension 14 (31.8) 9 (37.5) 5 (25)
Diabetes mellitus 2 (4.5) 0 2 (10)
Renal failure 13 (29.5) 2 (8.3) 11 (55)a
Glomerular filtration rate, ml/min 68 (55–75) 72.5 (66.5–82.5) 55.5 (45–67.5)b
Anemia 27 (61.4) 17 (70.8) 10 (50)
Hemoglobin, g/dl 12.1 (10.9–13.1) 11.7 (10.7–12.9) 12.5 (11.3–13.6)
Thrombocytopenia 14 (31.8) 8 (33.3) 6 (30)
Platelet count, × 103/µl 120 (93–151) 122 (95–155) 107 (90–148)
Prior stroke 5 (11.4) 0 5 (25)c
Prior myocardial infarction 3 (6.8) 1 (4.2) 2 (10)
Prior bleeding 12 (27.3) 2 (8.3) 10 (50)d
History of peptic ulcer 11 (25) 5 (20.8) 6 (30)
Time since AF diagnosis, mo 23 (18.5–45) 24 (19–47) 22.5 (17–42)
CHA2DS2‑VASc score ≥2 27 (61.4) 13 (54.2) 14 (70)
CHA2DS2‑VASc score, 0 5 (11.4) 3 (12.5) 2 (10)
HAS ‑BLED score ≥3 16 (36.4) 10 (41.7) 6 (30)
Types of AF Permanent 31 (70.5) 17 (70.8) 14 (70)
Persistent 10 (22.7) 5 (20.8) 5 (25)
Paroxysmal 3 (6.8) 2 (8.3) 1 (5)
Time since cancer diagnosis, mo 6 (5–7.5) 6 (5–7) 5.5 (5–9)
Prior surgical treatment 27 (61.4) 13 (54.2) 14 (70)
Palliative surgery 9 (20.5) 6 (25) 3 (15)
Metastatic disease 23 (52.3) 15 (62.5) 8 (40)
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reports.7,8 Recently, it has been recommended 
that NOACs should be preferred over warfarin 
in cancer patients receiving chemotherapy with 
newly diagnosed AF except for patients with gas‑
trointestinal cancer, based on data from trials 
on rivaroxaban and edoxaban in patients with 
venous thromboembolism.9 Our study showed 
that the use of NOACs was not associated with 
high risk of gastrointestinal bleeds, at least in 
patients with colorectal cancer after surgery and 
the first ‑line anticancer therapy.
This is probably the  largest study that fo‑
cused on patients with AF and colorectal can‑
cer receiving NOACs. Malavasi et al10 reported 
data from 394 cancer patients with AF, includ‑
ing 69 individuals with gastrointestinal cancer, 
of whom only 40% received antithrombotic ther‑
apy, including 3 patients on NOACs. In a Dan‑
ish population ‑based cohort study, the absolute 
risks of thromboembolic or bleeding complica‑
tions were similar in AF patients with and with‑
out cancer who redeemed prescription for vita‑
min K antagonists or NOACs.8
The current European Society of Cardiology 
guidelines recommend using NOACs at a reduced 
dose in patients with AF at high risk of gastro‑
intestinal bleeding (class IIa).11 Such a regimen 
was used in almost half of our patients. However, 
computed tomography angiography. Two major 
gastrointestinal bleedings occurred in patients 
on full‑dose apixaban and rivaroxaban 4 and 7 
months since NOAC initiation, respectively. Clin‑
ically relevant nonmajor bleedings were reported 
in 5 patients (11.4%, 2%/year), with a comparable 
distribution between the 2 NOAC regimens. Of 
these, 3 events (6.8%) were gastrointestinal bleed‑
ings requiring hospitalization. Major or clinically 
relevant nonmajor bleeds were not associated with 
thrombocytopenia; however, 2 patients had both 
metastatic disease and HAS‑BLED score equal to 
or higher than 3. No death was related to any re‑
corded hemorrhage or stroke. After adjustment 
for metastatic disease, the use of a reduced ‑dose 
NOAC independently predicted thromboembol‑
ic events (hazard ratio, 2.08; 95% CI, 1.05–4.17; 
P = 0.04) but not death.
DISCUSSION Our study showed that the use of 
NOACs in patients with AF and colorectal cancer 
could be an effective and safe option of anticoag‑
ulant therapy. We found that the use of NOACs 
was associated with a low incidence of throm‑
boembolism and an acceptable risk of bleeding, 
without any association with the CHA2DS2‑VASc 
or HASBLED scores, which is in line with other 
TABLE 1 Baseline characteristics and clinical outcomes of the studied patients (continued from the previous page)
Parameter All patients 
(n = 44)
Full dose of NOAC 
(n = 24)
Reduced dose of NOAC 
(n = 20)
Chemotherapy 30 (68.2) 17 (70.8) 13 (65)
Antithrombotic treatment Rivaroxaban 20 (45.5) 13 (54.2) 7 (35)
Apixaban 13 (29.5) 6 (25) 7 (35)
Dabigatran 11 (25) 5 (20.8) 6 (30)
NOAC initiation within 6 months since cancer diagnosis 16 (36.4) 6 (25) 10 (50)
Follow‑up
Follow ‑up, mo 28.5 (25–35.5) 25.5 (24–34.5) 30.5 (26.5–37)
NOAC withdrawal during follow ‑up 15 (34.1) 11 (45.8) 4 (20)
Time to NOAC withdrawal, mo 24 (20.5–32.5) 23 (20–33) 30 (25–32)
Clinical outcomes Stroke / transient ischemic attack 5 (11.4) 0 5 (25)
New deep vein thrombosis 2 (4.5) 0 2 (10)
Major bleeding 2 (4.5) 2 (8.3) 0
Clinically relevant non major bleeding 5 (11.4) 2 (8.3) 3 (15)
Gastrointestinal bleeding 3 (6.8) 1 (4.2) 2 (10)
Death 26 (59.1) 17 (70.8) 9 (45)
Cancer progression as a cause of death 22 (50) 15 (62.5) 7 (35)
Data are shown as number (percentage) or median (interquartile range).
a P = 0.001;  b P <0.001;  c P = 0.014;  d P = 0.005 for full vs reduced NOAC dose
Abbreviations: AF, atrial fibrillation; CHA2DS2‑VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or thromboembolism, 
vascular disease, age 65 to 74 years, female sex; HAS ‑BLED, hypertension, abnormal liver function, history of stroke or thromboembolism, history of bleeding, age ≥65 
years, use of nonsteroidal anti ‑inflammatory drugs, and alcohol abuse; NOAC, non–vitamin K antagonist oral anticoagulant








lower doses were associated with high throm‑
boembolic risk, suggesting that NOACs at a full 
dose may be preferable in cancer whenever pos‑
sible. The assessment of NOAC concentrations 
and improved knowledge on anticoagulation in 
AF may help optimize anticoagulant therapy.12-14 
Although the availability of idarucizumab might 
encourage physicians to prescribe dabigatran,15 
it was the least commonly used drug in our cohort. 
The study was too small to assess the outcomes 
of different NOACs in cancer patients.
Our single ‑center experience suggests that 
the use of NOACs might be an attractive an‑
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